Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 10,911 shares, an increase of 56.2% from the November 30th total of 6,987 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average trading volume of 27,579 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 27,579 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the company’s stock are short sold.

Evoke Pharma Stock Up 0.4%

Shares of NASDAQ:EVOK opened at $11.00 on Monday. The stock has a market cap of $18.92 million, a price-to-earnings ratio of -5.31 and a beta of -0.15. Evoke Pharma has a 12-month low of $1.94 and a 12-month high of $11.00. The business’s 50 day moving average is $9.53 and its 200 day moving average is $6.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Thursday, November 13th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, meeting analysts’ consensus estimates of ($0.45). Evoke Pharma had a negative return on equity of 101.40% and a negative net margin of 36.23%.The business had revenue of $4.28 million during the quarter, compared to analyst estimates of $4.33 million.

Insider Buying and Selling

In other Evoke Pharma news, major shareholder Roger M. Klein sold 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the sale, the insider owned 29,000 shares of the company’s stock, valued at approximately $308,850. This trade represents a 23.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.29% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. National Wealth Management Group LLC acquired a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned approximately 5.14% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on EVOK shares. Laidlaw cut Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Evoke Pharma in a report on Monday, December 15th. Finally, Wall Street Zen raised shares of Evoke Pharma to a “hold” rating in a research note on Saturday, December 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

About Evoke Pharma

Evoke Pharma, Inc is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology.